Wikipedia

Draft:Arda Ural

Arda Ural
Born1966
Ankara, Turkey
EducationPh.D
Alma materMarmara University
Known forErnst & Young
PartnerÇağla Ural
Children2

Arda Ural (born 1966, Ankara) is a Turkish-American businessman, known as the head of the Americas Health and Life Sciences sectors at Ernst & Young.[1][2][3][4]

Early life and education

edit

Ural received his early education from Istanbul Erkek Lisesi. He graduated from Marmara University with Bachelors in Mechanical Engineering and Masters in Materials Science. After graduating from the Business Administration Master's program at Marmara University, he completed his doctoral study titled "Success Factors of Global Pharmaceutical Companies in Emerging Markets" in the Finance Management Department of the same university.[5][6][7]

Career

edit

During his years at Boğaziçi University, Arda Ural appeared in various feature films and commercials.[8] Between 1989 and 1992, he worked as a research assistant in the Department of Material Science at Boğaziçi University's Faculty of Engineering. After joining Pfizer as a product manager in 1992, he was appointed to the company's headquarters in New York City, USA, in 1996.[9]

From 1997 to 1999, he served as the Product Development and International Marketing Manager in the team that launched the Viagra product worldwide.[10] From 1999 to 2001, he managed the Celecoxib drug group sold under the Celebrex brand in the USA.[11] In 2002, he played a leadership role in the establishment of EyeTech, a biotechnology company based in Manhattan, New York.[12][13] The biotechnology company introduced an anti-VEGF effective drug used in the treatment of blindness caused by age-related macular degeneration for the first time globally after receiving approval from the FDA. After the company's initial public offering,[14] he joined Becton Dickinson, an international medical technology company, in 2006 as Division President and Vice President of Strategic Marketing.[15]

In 2010, he transitioned to the consulting sector with Accenture, and since 2016, he has been working as the Head of the Americas Health and Life Sciences sectors at Ernst & Young, an international consulting firm.[16][17][18]

Arda Ural serves on the executive and advisory boards of various industry and academic organizations[19] including Co-Chair of the BioNJ (Biotechnology New Jersey) Organization C-Suite Summit[20][21], Member of the Business Advisory Board of the Biomedical Engineering Department at the New Jersey Institute of Technology (NJIT)[22] and Member of the Editorial Advisory Board of In Vivo[23], among others.

Publications

edit

Arda Ural has contributed to books and articles co-written with academics and business thought leaders.[24] He contributed to the book titled "Healthcare Disrupted," published by Wiley in 2016.[25] He also provides comments on pharmaceuticals, biotechnology, and healthcare topics to media outlets such as Harvard Business Review, Global Business Reports, and others in the USA.[26][27][28][29][30] In the Turkish media, he participates in publications such as Sabah, EkoTürk, HalkTV, and Para Analiz, providing global economic, geopolitical, and strategic insights.[31][32]

Some of his selected publications include:

  • “Cold Formability of Thermoplastic Sheets”, M.Sc. Thesis, Bosporus University Library, 1991.
  • “Contemporary Approaches in Manufacturing & Just-in-Time Management”, Journal of Contemporary Management, Vol. 6, July 1993, p.p. 184-196.
  • “Aligning the MSL Function for Coordinated Customer Focus”, Executive Forum: Maximizing the Effectiveness of Medical Liaison Team Capabilities, October 21, 2004, Philadelphia
  • “Industry Trends and Implications on the Biopharmaceutical Companies”, Cornell - Johnson School, Healthcare Biotech Club, November 7, 2011
  • “Global Biopharmaceutical Industry – Looking beyond the Cliff”, Cornell - Johnson School, Healthcare Biotech Club, November 15, 2012
  • “Key Success Factors for Global Pharmaceutical Companies in Emerging Markets” Ph.D. Thesis, Marmara University Library, 2014
  • "Investor and Entrepreneur Perspectives on Emerging Technologies” Columbia Business School Healthcare Conference New York City, January 2016
  • “Future Trends in MedTech Industry: Innovation and Consolidation”, MD&DI Conference, New York, May 2018
  • “Day in the life of a Partner”, Goizueta Business School, Emory University Consulting Club, October 2018

Personal life

edit

He resides in New Jersey, USA, with his wife Çağla Ural, and their two children.[33]

References

edit
  1. ^ Philippidis, Alex (2023-06-21). "As Patent Cliff Looms for Biopharma Giants, Smaller Biotechs Face Cash Crunch". GEN - Genetic Engineering and Biotechnology News. Retrieved 2024-09-05.
  2. ^ Gibney, Michael (Nov 21, 2022). "Why the biopharma 'IPO playbook' changed in 2022". PharmaVoice. Retrieved 2024-09-05.
  3. ^ Dunleavy, Kevin (2022-12-21). "2023 forecast: An 'inflection point' for biopharma, fueled by a flood of AI and machine learning products". Fierce Pharma. Retrieved 2024-09-05.
  4. ^ "Arda Ural". www.ey.com. Retrieved 2024-09-05.
  5. ^ "National Thesis Center | Homepage". tez.yok.gov.tr. Retrieved 2024-09-05.
  6. ^ "The Me-Suite: Working in Your Sweet Spot: Ikigai on Apple Podcasts". Apple Podcasts. Retrieved 2024-09-05.
  7. ^ Jay. "Arda Ural". DCAT Week. Retrieved 2024-09-05.
  8. ^ "Arda Ural | SinemaTürk". www.sinematurk.com. Retrieved 2024-09-05.
  9. ^ "Ufuk Eren´le 3,2,1: Dr. Arda Ural - Ufuk Eren ile 3,2,1". Spotify for Podcasters (in Turkish). Retrieved 2024-09-05.
  10. ^ "S A B A H O N L I N E 26.08.2000". arsiv.sabah.com.tr. Retrieved 2024-09-05.
  11. ^ "Arda Ural - BIO International Convention | BIO". www.bio.org. Retrieved 2024-09-05.
  12. ^ "FORM S-1". www.sec.gov. Retrieved 2024-09-05.
  13. ^ "Horyou". Horyou (in French). Retrieved 2024-09-05.
  14. ^ Staff. "FDA Approves Eyetech/Pfizer's Macugen". www.reviewofophthalmology.com. Retrieved 2024-09-05.
  15. ^ "Med Tech Trends: Innovation and Adaptation". event.on24.com. Retrieved 2024-09-05.
  16. ^ Talman, Kristen; Anderson, Maia (April 13, 2023). "Biotech may not be able to fend off M&A in the coming months, experts say". Healthcare Brew. Retrieved 2024-09-05.
  17. ^ Turmelle, Luther (2023-06-22). "CT biotech suspends operations in after failed merger". CT Insider. Retrieved 2024-09-05.
  18. ^ Adams, Helen Sydney (2023-10-10). "Revitalizing Medtech: EY's Insights on Post-Pandemic Headwinds and Industry Reshaping". healthcare-digital.com. Retrieved 2024-09-05.
  19. ^ "Arda Ural - BIO International Convention | BIO". www.bio.org. Retrieved 2024-09-05.
  20. ^ "2021 C-Suite Summit Program Book - Flip eBook Pages 1-21 | AnyFlip". anyflip.com. Retrieved 2024-09-05.
  21. ^ "Member Advisory & Forum Committees - BioNJ". November 6, 2022. Retrieved 2024-09-05.
  22. ^ "Advisory Boards < New Jersey Institute of Technology". catalog.njit.edu. Retrieved 2024-09-05.
  23. ^ "InVivo".
  24. ^ "Aneel Karnani | Michigan Ross". michiganross.umich.edu. Retrieved 2024-09-05.
  25. ^ Healthcare Disrupted (PDF).
  26. ^ Philippidis, Alex (June 21, 2023). "As Patent Cliff Looms for Biopharma Giants, Smaller Biotechs Face Cash Crunch". GEN - Genetic Engineering and Biotechnology News. Retrieved 2024-09-05.
  27. ^ "SCRIP Citeline Commercial".
  28. ^ Turmelle, Luther (June 22, 2023). "CT biotech suspends operations in after failed merger". NewsTimes. Retrieved 2024-09-05.
  29. ^ Elton, Jeff; Ural, Arda (October 23, 2014). "Predictive Medicine Depends on Analytics". Harvard Business Review. ISSN 0017-8012. Retrieved 2024-09-05.
  30. ^ "GBR - Arda Ural". www.gbreports.com. Retrieved 2024-09-05.
  31. ^ "Evde sağlık hizmetlerine talep artacak". Sabah (in Turkish). Retrieved 2024-09-05.
  32. ^ Uslu, Zeynep (November 26, 2021). "Arda Ural - Enflasyon ve Pandemi Hakkında". Sosyal Paraanaliz (in Turkish). Retrieved 2024-09-05.
  33. ^ "Ufuk Eren´le 3,2,1: Dr. Arda Ural - Ufuk Eren ile 3,2,1". Spotify for Podcasters (in Turkish). Retrieved 2024-09-05.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Arda_Ural&oldid=1244327244"